A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-16. Anything still debated is marked as such rather than presented as settled.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Odr-4 GPCR localization factor homolog, also known as C1orf27, is a protein in humans, encoded by the ODR4 gene. It is accession number NM_017847. This is a membrane protein that is 3926 base pairs long with the most extensive string of amino acids being 454aa long. C1orf27 exhibits cytoplasmic expression in epidermal tissues. Predicted associated biological processes of the gene include cell fate specification and developmental properties.
==== Estimating uncertainty ==== It is often important for human operators to gauge how much they should trust an AI system, especially in high-stakes settings such as medical diagnosis. ML models generally express confidence by outputting probabilities; however, they are often overconfident, especially in situations that differ from those that they were trained to handle. Calibration research aims to make model probabilities correspond as closely as possible to the true proportion that the model is correct. Similarly, anomaly detection or out-of-distribution (OOD) detection aims to identify when an AI system is in an unusual situation. For example, if a sensor on an autonomous vehicle is malfunctioning, or it encounters challenging terrain, it should alert the driver to take control or pull over. Anomaly detection has been implemented by simply training a classifier to distinguish anomalous and non-anomalous inputs, though a range of additional techniques are in use.
== History == Food technologists have long known that protein hydrolysis produces a meat bouillon-like odor and taste. Hydrolysates have been a part of the human diet for centuries, notably in the form of fermented soy sauce, or Shoyu. Shoyu, traditionally made from wheat and soy protein, has been produced in Japan for over 1,500 years, following its introduction from mainland China. The origins of producing these materials through the acid hydrolysis of protein (aHVP) can be traced back to the scarcity and economic challenges of obtaining meat extracts during the Napoleonic wars. In 1831, Berzelius obtained products having a meat bouillon taste when hydrolysing proteins with hydrochloric acid. Julius Maggi produced acid-catalyzed hydrolyzed vegetable protein industrially for the first time in 1886. In 1906, Fischer found that amino acids contributed to the specific taste. In 1954, D. Phillips found that the bouillon odor required the presence of proteins containing threonine. Another important substance that gives a characteristic taste is glutamic acid.
=== PVAT AND ET-1 === ET-1 In addition to its direct vasoconstrictor effects, it causes changes in visceral and perivascular adipose tissue (PVAT), and may contribute to the pathogenesis of both insulin resistance and vascular dysfunction/damage. Perivascular adipose tissue seems to have anti contractile effect and this dilator effect was lost in obese patients. secondary to obesity, ET-1 high level changes on PVAT will lead to PVAT hypertrophy which will be associated with reduced partial oxygen pressure, an increase in the production of inflammatory cytokines such as TNF-α and IL-6, and elevation of reactive oxygen species. Thus, oxidative stress and hypoxia may promote imbalance in the production of vasoactive compounds and may affect vascular homeostasis by activating the ET-1 system.
Works by Marguerite Yourcenar at Open Library Petri Liukkonen. "Marguerite Yourcenar". Books and Writers. Stockinger, Jacob (3 March 2004) [2002]. "Yourcenar, Marguerite (1903–1987)". In Summers, Claude J. (ed.). glbtq: An encyclopedia of gay, lesbian, bisexual, transgender, and queer culture. Chicago: glbtq, Inc. Archived from the original on 16 January 2009. Marguerite Yourcenar et Suzanne Lilar : plus qu’une rencontre, une complicité by Michèle Goslar English translations of Marguerite Yourcenar by Walter Jacob Kaiser, Catalogue of correspondence and manuscripts concerning Walter Kaiser's English translation of works by French writer Marguerite Yourcenar, Houghton Library, Harvard University Accueil
Sources: en.wikipedia.org
Due to widespread resistance to many common first-line antibiotics, carbapenems, polymyxins, and more recently tigecycline were considered to be the drugs of choice; however, resistance to these drugs has also been reported. Despite this, they are still being used in areas where resistance has not yet been reported. Use of β-lactamase inhibitors such as sulbactam has been advised in combination with antibiotics to enhance antimicrobial action even in the presence of a certain level of resistance. Combination therapy after rigorous antimicrobial susceptibility testing has been found to be the best course of action in the treatment of multidrug-resistant P. aeruginosa. Some next-generation antibiotics that are reported as being active against P. aeruginosa include doripenem, ceftobiprole, and ceftaroline. However, these require more clinical trials for standardization. Therefore, research for the discovery of new antibiotics and drugs against P. aeruginosa is very much needed. Antibiotics that may have activity against P. aeruginosa include:
== See also == 11-Hydroxy-Delta-8-THC 11-Hydroxyhexahydrocannabinol 3'-Hydroxy-THC 7-Hydroxycannabidiol 10-Hydroxy-THC 8,11-Dihydroxytetrahydrocannabinol 11-Hydroxycannabinol Cannabis edible Delta-11-Tetrahydrocannabinol
Executive mental function was measured with standard tests, including the ability to say the sequence 1-A, 2-B, 3-C..., to name a number of animals in one minute, and with the Stroop test. The study found that those individuals with lower skeletal muscle mass at the start of the study declined in their executive mental function considerably more sharply than those with higher muscle mass. Memory, as well as psychomotor speed, on the other hand, did not correlate with skeletal muscle mass. Thus, larger muscle mass, with a concomitantly larger secretome, appeared to have the endocrine function of protecting the executive mental function of individuals over the age of 65.
In their discovery of elements 99 and 100, the American teams had competed with a group at the Nobel Institute for Physics, Stockholm, Sweden. In late 1953 to early 1954, the Swedish group succeeded in synthesizing light isotopes of element 100, in particular 250Fm, by bombarding uranium with oxygen nuclei. These results were also published in 1954. Nevertheless, the priority of the Berkeley team was generally recognized, as its publications preceded the Swedish article, and they were based on the previously undisclosed results of the 1952 thermonuclear explosion; thus the Berkeley team was given the privilege to name the new elements. As the effort which had led to the design of Ivy Mike was codenamed Project PANDA, element 99 had been jokingly nicknamed "Pandemonium" but the official names suggested by the Berkeley group derived from two prominent scientists, Einstein and Fermi: "We suggest for the name for the element with the atomic number 99, einsteinium (symbol E) after Albert Einstein and for the name for the element with atomic number 100, fermium (symbol Fm), after Enrico Fermi." Both Einstein and Fermi died between the time the names were originally proposed and when they were announced. The discovery of these new elements was announced by Albert Ghiorso at the first Geneva Atomic Conference held on 8–20 August 1955. The symbol for einsteinium was first given as "E" and later changed to "Es" by IUPAC.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.